Vertigenius, an Irish start-up company focussed on the treatment of vertigo, has announced the close of a €2.55m funding round to drive its growth in the US.
The company has produced a wearable head sensor and software that allows therapists to prescribe and track exercises carried out by patients, monitor patient symptoms and gain insights into the effectiveness of treatments.
The technology helps patients to carry out at-home rehabilitation exercises correctly.
The investment being announced today, which follows a €2.1m fundraising round in 2024, was led by Atlantic Bridge and supported by Enterprise Ireland, MedTech Syndicate, IRRUS Investments, Xcendra Ventures, Ascentifi and others.
With FDA registration complete, Vertigenius launched in the US market in October 2025.
20 clinics across 11 US states are now using the device and 3,000 patients have been treated.
Over the next five years, Vertigenius said it is planning to expand further in Europe and enter other markets including Asia Pacific.
The company said it will use the new funding to grow its US commercial team.
The investment will also fund hiring in clinical research, product R&D, quality assurance and regulatory affairs, all of which will continue to be based in its Irish headquarters.
"This investment marks an exciting new chapter for Vertigenius as we move into the world's largest market for vestibular care," said Mark Barry, CEO, Vertigenius.
"The early traction we have seen in the US validates both the clinical value of our platform and the commercial opportunity," Mr Barry said.
Conor O’Sullivan, Investment Director of Atlantic Bridge, said Vertigenius is addressing a significant gap in vestibular care in a multi-billion dollar market.
"The team has built a unique platform that is significantly enhancing the delivery of vestibular care by supporting clinicians and patients between visits, and we are excited to back their US expansion," Mr O'Sullivan said.
